Evidence map›Paper›PMID 33010021›Full record

ReviewNeurology and therapy2020

An Evidence-Based Review of Galcanezumab for the Treatment of Migraine.

Ivan Urits, Melis Yilmaz, Karina Charipova, Kyle Gress, Ehab Bahrum, Michael Swett, Amnon A Berger, Hisham Kassem, Anh L Ngo, Elyse M Cornett and 2 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurology and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Ivan UritsDepartment of Anesthesiology, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. iurits@bidmc.harvard.edu.
Melis YilmazHarvard Medical School, Boston, MA, USA.
Karina CharipovaGeorgetown University School of Medicine, Washington, DC, USA.
Kyle GressGeorgetown University School of Medicine, Washington, DC, USA.
Ehab BahrumGeorgetown University School of Medicine, Washington, DC, USA.
Michael SwettGeorgetown University School of Medicine, Washington, DC, USA.
Amnon A BergerDepartment of Anesthesiology, Critical Care, and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Hisham KassemDepartment of Anesthesiology, Mount Sinai Medical Center, Miami Beach, FL, USA.
Anh L NgoHarvard Medical School, Boston, MA, USA.
Elyse M CornettDepartment of Anesthesiology, Louisiana State University Health Sciences Center, New Orleans, LA, USA.
Alan D KayeDepartment of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, USA.
Omar ViswanathDepartment of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA, USA.
Georgetown University · USHarvard University · USBeth Israel Deaconess Medical Center · USChildren's Specialty Group · USLouisiana State University Health Sciences Center New Orleans · USLouisiana State University in Shreveport · USMount Sinai Medical Center · USUniversity of Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis is a comprehensive review of the current literature on the usage of galcanezumab for migraine treatment. It reviews the biology, pathophysiology, epidemiology, diagnosis, and conventional treatment of migraines, then compares the literature available for galcanezumab with historical treatment options. RECENT

findingsMigraine is a common headache disorder and constitutes a significant source of distress from both a personal and societal perspective. Conventional treatment includes abortive and preventive treatment. Treatment options are limited and may be only partially or minimally effective in some of the population. Recent evidence points to metabolic changes in the brain as possible causes of migraine, via reduced available energy or a spiking need for it, resulting in a relative insufficiency. This leads to trigeminocervical complex (TCC) activation and a headache episode, modulated by calcitonin gene-related peptide (CGRP). Galcanezumab (Emgality) is a monoclonal antibody targeting CGRP that is given in a monthly injection for the prevention of migraines. Its safety was previously shown in phase 1 and 2 trials, and recent phase 3 trials showed efficacy, with up to 50% reduction in monthly migraine days and improved functional capacity in migraineurs. Studies show that the drug is well tolerated and safe. Migraine headache is a common neurological syndrome that causes great pain and suffering. Treatment options today are limited. Galcanezumab does not prevent migraines, but it is effective in decreasing their frequency and length. It is also much better tolerated than the currently existing therapies. While it is unlikely to provide monotherapy for migraines, it is a novel therapy that may be added for cases of severe or frequent migraines.

Indexed as

CGRPChronic painGalcanezumabHeadacheMigraineMonoclonal antibody

Identifiers

PMID33010021
PMCPMC7606392
OpenAlexW3091538692

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.